blood withdrawn

Phase 3Biologic

Emergent BioSolutions

blood withdrawn is one of 291 biologic programs targeting Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

290

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

AsthmaActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Antiphospholipid SyndromeActive, not recruiting

PreeclampsiaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

ARTUnknown status

InteractionCompleted

Elderly PatientsCompleted

Anal CarcinomaActive, not recruiting

HepatitisPreclinical

Active, not recruiting

AsthmaPreclinical

Active, not recruiting

Idiopathic Pulmonary FibrosisPreclinical

Active, not recruiting

Antiphospholipid SyndromePreclinical

Active, not recruiting

PreeclampsiaPreclinical

Active, not recruiting

Chronic Lymphocytic LeukemiaPreclinical

Active, not recruiting

ARTPreclinical

Unknown status

InteractionPreclinical

Completed

Elderly PatientsPreclinical

Completed

Anal CarcinomaPhase 2

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

blood withdrawn

Emergent BioSolutions

Phase 3

1 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Aclidinium Bromide

AstraZeneca

Preclinical

—8

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 9

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 10

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Recruiting

Hepatitis

NCT06470997

Q2 2028

Recruiting

Bone Loss

NCT04883502

N/ARecruiting

Chronic Lymphocytic Leukemia

NCT06475469

Clinical

Trials by Indication[1]

Elderly Patients1 trial

Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer

Completed·CCHU de Reims·N/A·NCT02807129·296 enrolled

ART1 trial

Patient With Any Pathology (According to the Appreciation of the Investigator) Which Could Disturb the Participation in the Study

Unknown status·CCHU de Reims·N/A·NCT02793427·160 enrolled

Hepatitis1 trial

Specific Biomarkers of Immune-mediated Hepatitis Secondary to Immune Checkpoint Inhibitors

Recruiting·UUniversity Hospital, Montpellier··NCT06470997·60 enrolled

Bone Loss1 trial

Study of the Role of the Induced Membrane in the Reconstruction of Bone Loss in the Limbs

Recruiting·DDirection Centrale du Service de Santé des Armées··NCT04883502·80 enrolled

Acoustic Trauma1 trial

Study of Diagnostic Biomarkers of Acute Acoustic Trauma

Unknown status·DDirection Centrale du Service de Santé des Armées··NCT04832230·500 enrolled

15 more indications

Idiopathic Pulmonary Fibrosis1 trial

Idiopathic Pulmonary Fibrosis and Serum Bank

Completed·RRennes University Hospital··NCT04016168·903 enrolled

Preeclampsia1 trial

First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography

Completed·—·N/A·NCT03342014·2,159 enrolled

Pediatric Patients1 trial

BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients

Enrolling by invitation· Emergent BioSolutions logo

Emergent BioSolutions·Phase 4·NCT02051062·10 enrolled

Neuroendocrine Tumors1 trial

Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors

Completed·CCHU de Reims·N/A·NCT02826928·116 enrolled

Coronary Syndrome1 trial

Markers of Vascular Aging and Coronary Syndrome

Completed·CCHU de Reims·N/A·NCT02857387·65 enrolled

Intravitreal Injections1 trial

Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF

Completed·CCalifornia Retina Consultants·Phase 1/2·NCT02118831·56 enrolled

Asthma1 trial

Analysis of Sexual Bias in Type 2 Innate Lymphoid Cells (ILC2) in Asthmatic Patients

Completed·UUniversity Hospital, Toulouse··NCT04384835·34 enrolled

Immune Response1 trial

Immune Response and Risk of Serious Infection to SARS-Cov2

Completed·—··NCT04410432·39 enrolled

Anal Carcinoma1 trial

Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.

Active, not recruiting·—·Phase 2·NCT04719988·55 enrolled

SARS-CoV-21 trial

Understanding the Determinants of Mucosal Immunity and Optimizing the Diagnosis of Infection With SARS-CoV-2 Variants

Recruiting·IInstitut Pasteur·N/A·NCT05858502·90 enrolled

Interaction1 trial

Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Completed·CCHU de Reims·N/A·NCT02818465·100 enrolled

Papilloma1 trial

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)

Completed·—·Phase 2·NCT03946358·47 enrolled

Antiphospholipid Syndrome1 trial

Multi-organ Screening for Asymptomatic Ischaemia in Antiphospholipid Syndrome

Completed·—·N/A·NCT03348306·50 enrolled

Chronic Lymphocytic Leukemia1 trial

Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk

Recruiting·CCHU de Reims·N/A·NCT06475469·75 enrolled

Prospective1 trial

Pre-therapeutic Analysis of the Individual Radiosensitivity of Cancer Patients in Luxembourg (APRI-Lux): Prospective National Interventional Study With Minimal Risk

Unknown status·CCentre Francois Baclesse, Luxembourg·N/A·NCT05433974·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for blood withdrawn. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — blood withdrawn compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for blood withdrawn. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emergent BioSolutions company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Emergent BioSolutions

blood withdrawn

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Trials by Indication[1]

Elderly Patients1 trial

ART1 trial

Hepatitis1 trial

Bone Loss1 trial

Acoustic Trauma1 trial

Idiopathic Pulmonary Fibrosis1 trial

Preeclampsia1 trial

Pediatric Patients1 trial

Neuroendocrine Tumors1 trial

Coronary Syndrome1 trial

Intravitreal Injections1 trial

Asthma1 trial

Immune Response1 trial

Anal Carcinoma1 trial

SARS-CoV-21 trial

Interaction1 trial

Papilloma1 trial

Antiphospholipid Syndrome1 trial

Chronic Lymphocytic Leukemia1 trial

Prospective1 trial

References

Drug Info

Quick Facts

Related News